Infectious disease
In the U.S., many states and organizations are using unique tactics to improve vaccination rates including setting up mobile vans, offering $100 incentives, and free beers.
New mutations of the SARS-CoV-2 virus are continuing to be discovered. As we’ve seen from the most common variants of the virus, infectiousness appears to be the trait most familiar to all of them.
The U.S. FDA expanded the Emergency Use Authorization for the Pfizer and BioNTech vaccine to include adolescents ages 12 to 15 after clinical data showed 100% efficacy response.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 11, 2021.
The CDC says that COVID-19 is an airborne threat, stating that transmission and subsequent infection can occur via inhalation of very fine respiratory droplets and aerosolized particles.
Researchers are now concerned that the same health inequalities that have made certain racial and ethnic groups experience higher infection and death rates also drive disparities in treatment for long Covid.
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
It was a busy week for clinical trial news. Here’s a look.
On Thursday, Pfizer Chief Executive Officer Albert Bourla who is “not at all” in favor of the U.S. position, stated that the real challenge is manufacturing capacity.
Six months after receiving Emergency Use Authorization from the U.S. FDA for COVID-19 vaccines, Pfizer/BioNTech and Moderna are planning to seek full approval for the preventative medications.
PRESS RELEASES